a(PUBCHEM:400769)

Entity

Name

400769

Namespace

PUBCHEM

Namespace Version

None

Pattern

^\d+$

Patients with relapsing-remitting multiple sclerosis treated with BG-12 for 24 weeks showed significantly fewer new gadolinium-enhancing lesions, with significantly reduced probability of their evolution to T1-hypointense lesions than patients treated with placebo (Macmanus et al., 2011) PubMed:22020111

The greatest FImax was observed with Protandim at 135-fold, followed by bardoxolone methyl at 67-fold, dimethyl fumarate at 55-fold, and sulforaphane at 21-fold PubMed:22020111

Bardoxolone methyl appeared to produce a biphasic induction, producing near maximal FI over a range of concentrations from less than 40 nM to 0.4 lM PubMed:22020111

When compared contemporaneously in the AREc32-based assay, FImax observed was in the order Protandim > bardoxolone methyl > dimethyl fumarate > sulforaphane. PubMed:22020111

While Protandim, bardoxolone methyl, BG-12, and sulforaphane all have been demonstrated to modify gene expression profiles by activation of Nrf2, they have not been compared side by side, in the same cell line, under identical conditions. PubMed:22020111

After 52 weeks, the estimated glomerular filtration rate in the 75 mg/day treatment group had increased by 10.5 ± 1.8 ml/min/1.73 m2 (p < 0.001), representing an increase of about 32% when compared to entry values. PubMed:22020111

Patients with relapsing-remitting multiple sclerosis treated with BG-12 for 24 weeks showed significantly fewer new gadolinium-enhancing lesions, with significantly reduced probability of their evolution to T1-hypointense lesions than patients treated with placebo (Macmanus et al., 2011) PubMed:22020111